Address: Energieweg 1, 3641 RT, Mijdrecht,Netherlands
Tel: +31 297 28 06 66
Web: http://www.bayer.nl/ebbsc/cms/nl/index.html
Bayer’s presence in the Netherlands segments Bayer HealthCare, Bayer CropScience and Bayer MaterialScience. The main markets for Bayer products in the Netherlands are health, agriculture, construction and automotive industries. The three segments in our land will yield about 500 million euros in turnover of the parent group and employs around 600 people.
Bayer HealthCare’s aim is to human and animal health promotion. With innovative products, we are improving the welfare and quality of life by diagnosing, preventing and treating diseases.
Bayer HealthCare comprises four divisions. Bayer Shering Pharma, Animal Health, Consumer Care and Diabetes Care. There are more than 53,400 people work for Bayer HealthCare.
The business units of the division Bayer Schering Pharma – General Medicine, Specialized Therapeutics, Hematology / Oncology, Diagnostic Imaging – have medicines to treat diseases such as cancer, cardiovascular diseases, infections, immune and metabolic disorders, multiple sclerosis. There are also funds for contraception, erectile problems and products for imaging (contrast media).
New methodology for the 2024 Access to Medicine Index promises a stronger attempt to quantify whether drugs, vaccines, and diagnostics are actually making it all the way to patients in…
Claudia Martínez, generic & biosimilar medicines programme manager at the Access to Medicine Foundation, draws from a recent AMF report to outline what more generics companies can be doing to…
As part of a wide-ranging conversation with PharmaBoardroom published earlier this month, European Medicines Agency (EMA) Executive Director Emer Cooke laid out four of the Agency’s core focus areas for…
In conversation at DIA Europe 2023 in Basel, European Medicines Agency Executive Director Emer Cooke looks back at the lessons EMA has taken from the COVID-19 pandemic response, outlines the…
The Access to Medicine Index, a biennial report that gauges the efforts of the world’s largest pharma companies to expand access in low- and middle-income countries (LMICs), found in this…
The latest news from the Dutch pharma, biotech and healthcare industries, including the bullish comments of Argenx CEO Tim Van Hauwermeiren following the successful launch of its Vyvgart product; cancer…
The European Medicines Agency (EMA), the EU body responsible for the evaluation of medicinal products for use within the European Union, concluded a vote on Monday evening in Brussels following…
Leo de Haan of Aurobindo discusses how to maintain a profitable business in times of rock-bottom generics prices in the Netherlands, the resulting second pillar of specialty products for the…
Despite lacking a national champion to bolster its innovative eco-system since the 2007 acquisition of Organon by Schering Plough, the Netherlands nevertheless still sits in fourth position on the 2015…
The Netherlands is clearly a fertile environment for its 2,200 life science and medtech companies. However, the Dutch ambition to be a frontrunner in new healthcare challenges also comprises an…
Sobi is a leading integrated biopharmaceutical company dedicated to developing innovative therapies and services to improve the lives of rare disease patients and their families. Karel Fol, the country manager…
Paul Korte, General Manager for Janssen in the Netherlands, highlights the strategic move and leadership position taken up by Janssen in the oncology field, and calls on Dutch healthcare stakeholders…
See our Cookie Privacy Policy Here